An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

Completed · Phase 3

Conditions studied: Eosinophilic Gastritis, Eosinophilic Duodenitis

In brief

This is a Phase 3, open-label, extension study to assess the long term efficacy and safety of lirentelimab given monthly.

Key facts

Study ID

NCT04620811

Run by

Allakos Inc.

People needed

159

Starts

2020-12-03

Expected to finish

2023-07-07

Last updated by the study team

2024-04-22

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Allakos Investigational Site 216-068 — Birmingham, Alabama, United States
• Allakos Investigational Site 216-002 — Huntsville, Alabama, United States
• Allakos Investigational Site 216-035 — Phoenix, Arizona, United States
• Allakos Investigational Site 216-032 — Chula Vista, California, United States
• Allakos Investigational Site 216-014 — Santa Monica, California, United States
• Allakos Investigational Site 216-038 — Tustin, California, United States
• Allakos Investigational Site 216-049 — Walnut Creek, California, United States
• Allakos Investigational Site 216-034 — Aurora, Colorado, United States
• Allakos Investigational Site 216-063 — Brandon, Florida, United States
• Allakos Investigational Site 216-027 — Edgewater, Florida, United States
• Allakos Investigational Site 216-056 — Jacksonville, Florida, United States
• Allakos Investigational Site 216-013 — Miami, Florida, United States
• Allakos Investigational Site 216-053 — New Port Richey, Florida, United States
• Allakos Investigational Site 216-007 — Chicago, Illinois, United States
• Allakos Investigational Site 216-001 — Crowley, Louisiana, United States
• Allakos Investigational Site 216-026 — Boston, Massachusetts, United States
• Allakos Investigational Site 216-052 — Boston, Massachusetts, United States
• Allakos Investigational Site 216-051 — Boston, Massachusetts, United States
• Allakos Investigational Site 216-005 — Rochester, Minnesota, United States
• Allakos Investigational Site 216-042 — Kansas City, Missouri, United States
• Allakos Investigational Site 216-045 — Reno, Nevada, United States
• Allakos Investigational Site 216-025 — New York, New York, United States
• Allakos Investigational Site 216-020 — Chapel Hill, North Carolina, United States
• Allakos Investigational Site 216-048 — Durham, North Carolina, United States
• Allakos Investigational Site 216-050 — Winston-Salem, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.